MDxHealth Future Growth
Future criteria checks 0/6
MDxHealth is forecast to grow earnings and revenue by 49% and 8% per annum respectively while EPS is expected to grow by 60.4% per annum.
Key information
49.0%
Earnings growth rate
60.43%
EPS growth rate
| Biotechs earnings growth | 27.7% |
| Revenue growth rate | 8.0% |
| Future return on equity | n/a |
| Analyst coverage | Good |
| Last updated | 17 Aug 2026 |
Recent future growth updates
Recent updates
MDXH: Future Upside Will Hinge On Resolving The 10.4m Medicare Recoupment
Analysts have reset expectations for MDxHealth, cutting price targets from as high as $9 to a range of $1.50 to $5, as they factor in weaker Q1 results, the exit from the Resolve UTI business, and reimbursement uncertainty that affects revenue growth, profit margin assumptions, and the future P/E multiple. Analyst Commentary Recent Street commentary around MDxHealth reflects a more cautious tone, with several bearish analysts reassessing the risk profile after weaker Q1 results, the planned exit from the Resolve UTI business, and questions around Medicare reimbursement.
MDXH: Resolve Exit And Medicare Review Will Reset Prostate Cancer Focus
Analysts have sharply reduced their price targets on MDxHealth, with cuts such as $7 to $1.50, $9 to $5, and $7 to $4, reflecting weaker Q1 revenue, lowered guidance, and the exit of the Resolve UTI business following reimbursement and recoupment disputes. Analyst Commentary Recent research on MDxHealth highlights a mix of caution and optimism, with analysts reacting to weaker Q1 revenue, revised guidance, and the exit of the Resolve UTI business.MDXH: Resolve Exit And Medicare Review Will Refocus On Prostate Cancer
Analysts have cut their fair value estimate for MDxHealth from $9.00 to $5.00, citing reduced revenue growth assumptions, a higher discount rate, and a lower future P/E multiple after the Q1 miss, the Resolve exit, and reimbursement uncertainties. Analyst Commentary Recent Street research on MDxHealth reflects a reset in expectations after the Q1 shortfall, the Resolve exit, and reimbursement questions, but also highlights areas where analysts still see potential for execution and valuation recovery.MDXH: Future Upside Will Depend On Resolving The 10.4m Medicare Dispute
Analysts have reduced their fair value estimate for MDxHealth from $4.20 to $1.00 following weak Q1 results, lower revenue guidance, the discontinuation of the Resolve UTI test, and uncertainty surrounding a $10.4m Medicare recoupment notice and the closure of the related Texas lab. Analyst Commentary on MDxHealth Recent Street research on MDxHealth highlights a clear shift toward caution, with several bearish analysts cutting price targets and reassessing the risk profile after the weak Q1 update, reduced revenue guidance, the Medicare recoupment notice of $10.4m, and the decision to close the Texas lab tied to the Resolve UTI test.MDxHealth SA (NASDAQ:MDXH) Looks Inexpensive After Falling 28% But Perhaps Not Attractive Enough
MDxHealth SA ( NASDAQ:MDXH ) shareholders won't be pleased to see that the share price has had a very rough month...Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2028 | 137 | -12 | 3 | 7 | 2 |
| 12/31/2027 | 126 | -23 | -3 | -2 | 6 |
| 12/31/2026 | 112 | -34 | -9 | -9 | 6 |
| 6/30/2026 | 114 | -36 | -6 | -5 | N/A |
| 3/31/2026 | 111 | -33 | -2 | -1 | N/A |
| 12/31/2025 | 108 | -34 | -3 | -2 | N/A |
| 9/30/2025 | 103 | -31 | -7 | -6 | N/A |
| 6/30/2025 | 99 | -35 | -14 | -13 | N/A |
| 3/31/2025 | 95 | -39 | -18 | -16 | N/A |
| 12/31/2024 | 90 | -38 | -21 | -19 | N/A |
| 9/30/2024 | 85 | -42 | -26 | -23 | N/A |
| 6/30/2024 | 81 | -41 | -25 | -21 | N/A |
| 3/31/2024 | 75 | -40 | -27 | -23 | N/A |
| 12/31/2023 | 70 | -43 | -27 | -21 | N/A |
| 9/30/2023 | 64 | -45 | -30 | -24 | N/A |
| 6/30/2023 | 55 | -48 | -35 | -29 | N/A |
| 3/31/2023 | 46 | -47 | -34 | -30 | N/A |
| 12/31/2022 | 37 | -44 | -38 | -34 | N/A |
| 9/30/2022 | 30 | -40 | -32 | -30 | N/A |
| 6/30/2022 | 25 | -34 | -28 | -26 | N/A |
| 3/31/2022 | 23 | -31 | N/A | N/A | N/A |
| 12/31/2021 | 22 | -29 | -23 | -23 | N/A |
| 9/30/2021 | 21 | -28 | -22 | -21 | N/A |
| 6/30/2021 | 19 | -28 | -21 | -21 | N/A |
| 3/31/2021 | 19 | -28 | N/A | N/A | N/A |
| 12/31/2020 | 18 | -29 | -21 | -20 | N/A |
| 9/30/2020 | 15 | -36 | -20 | -20 | N/A |
| 6/30/2020 | 11 | -43 | -20 | -20 | N/A |
| 3/31/2020 | 11 | -43 | N/A | -21 | N/A |
| 12/31/2019 | 12 | -43 | N/A | -22 | N/A |
| 9/30/2019 | 17 | -37 | N/A | -25 | N/A |
| 6/30/2019 | 22 | -31 | N/A | -27 | N/A |
| 3/31/2019 | 25 | -32 | N/A | -28 | N/A |
| 12/31/2018 | 28 | -32 | N/A | -29 | N/A |
| 9/30/2018 | 31 | -30 | N/A | -28 | N/A |
| 6/30/2018 | 33 | -28 | N/A | -27 | N/A |
| 3/31/2018 | 37 | -20 | N/A | -19 | N/A |
| 12/31/2017 | 41 | -12 | N/A | -10 | N/A |
| 9/30/2017 | 41 | -9 | N/A | -8 | N/A |
| 6/30/2017 | 41 | -5 | N/A | -5 | N/A |
| 3/31/2017 | 36 | -9 | N/A | -11 | N/A |
| 12/31/2016 | 30 | -13 | N/A | -17 | N/A |
| 9/30/2016 | 26 | -15 | N/A | -17 | N/A |
| 6/30/2016 | 23 | -17 | N/A | -16 | N/A |
| 3/31/2016 | 20 | -16 | N/A | -15 | N/A |
| 12/31/2015 | 18 | -14 | N/A | -14 | N/A |
| 9/30/2015 | 16 | -14 | N/A | -15 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: MDXH is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: MDXH is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: MDXH is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: MDXH's revenue (8% per year) is forecast to grow slower than the US market (12.9% per year).
High Growth Revenue: MDXH's revenue (8% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if MDXH's Return on Equity is forecast to be high in 3 years time
Discover growth companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/08/21 14:38 |
| End of Day Share Price | 2026/08/20 00:00 |
| Earnings | 2026/06/30 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
MDxHealth SA is covered by 14 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Michael Ruzic-Gauthier | Berenberg |
| Mark Massaro | BTIG |
| William Bonello | Craig-Hallum Capital Group LLC |